Sodium load in novel antibiotics – an underrecognized factor in clinical settings

Abstract Recent advances in antimicrobial therapy have led to the development of several novel antibiotics that have substantially improved outcomes in infections caused by resistant pathogens. However, these therapeutic gains are not without risk. An underrecognized concern is the sodium content of certain intravenous antibiotics, which may significantly contribute to total daily sodium intake and, in some cases, exceed recommended physiological limits. This additional sodium burden may be clinically relevant in sodium-sensitive populations, including patients with heart failure, chronic kidney disease, or liver cirrhosis. Greater awareness of this factor may help clinicians individualize antimicrobial therapy and may reduce avoidable volume- and electrolyte-related complications , particularly in vulnerable patients.